Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

N/A Completed NCT04657523

Condition	Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Phase	N/A
Sponsor	Philips Clinical & Medical Affairs Global
Status	Completed
Enrollment	60 participants
Interventions	Investigational Liver Fat Quantification Software
Start date	Oct 30, 2020
Completion date	Jan 18, 2023
Results posted	Jan 23, 2026

Summary

This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The primary objective of this clinical study is to evaluate the clinical feasibility of an investigational ultrasound technique for quantifying liver fat by comparing specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo two investigational abdominal ultrasound examinations using the Philips EPIQ Ultrasound System and one MRI PDFF examination according to the clinical standard of care.

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements Hepatorenal Index (HRI) of Ultrasound Biomarkers for Liver Fat.

Intra-procedural (1 day) · Hepatorenal Index

Investigational Ultrasound Imaging for Liver Fat Quantification	1.6 ± 0.7 Hepatorenal Index

Pearson correlation coefficient	0.5749

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Acoustic Attenuation (dB/cm/MHZ) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · dB/cm/MHZ

Investigational Ultrasound Imaging for Liver Fat Quantification	1.0 ± 0.7 dB/cm/MHZ

Pearson correlation coefficient	0.6824

Correlation of the Liver Fat Percentage Reported From MRI-PDFF With Measurements of Tissue Stiffness (kPa) Ultrasound Biomarker for Liver Fat.

Intra-procedural (1 day) · kPa

Investigational Ultrasound Imaging for Liver Fat Quantification	5.9 ± 1.8 kPa

Pearson correlation coefficient	-0.0539

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский